Drug Profile
Research programme: herpes simplex virus-2 vaccines - BlueWillow Biologics
Alternative Names: Nanoemulsion adjuvanted intramuscular HSV-2 vaccine - BlueWillow Biologics; Nanoemulsion adjuvanted intranasal HSV-2 vaccine - BlueWillow Biologics; NE glycoprotein vaccine - BlueWillow Biologics; NE HSV-2 vaccine; NE-HSV2Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator NanoBio Corporation
- Developer BlueWillow Biologics
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Herpes simplex virus type 2 infections
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections in USA (Intranasal)
- 09 Mar 2020 Research programme: herpes simplex virus-2 vaccines is still in preclinical development in Herpes simplex virus type-2 infections in USA (Intranasal) (BlueWillow Biologics pipeline March 2020)
- 09 Mar 2020 No development reported - Preclinical for Herpes simplex virus type 2 infections in USA (IM) (BlueWillow Biologics pipeline March 2020)